English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In this study, we calculated the ratio of the serum contributions of two highly studied fluorophore products (advanced glycation end products AGEs and kynurenine KYN) in the area of nutrition and metabolic diseases including diabetes mellitus (DM), by using a non-invasive, economical and easy-to-perform method. Blood serum spectrofluorimetric analysis was performed both in the case of normoglycemic (n=10) and diabetic rats (n=10), and in the case of non-diabetic (n=14) and type 2 diabetes mellitus (T2DM) patients (n=52). Our results showed a significant increase in the contributions of the two products in diabetic patients and rats compared to the control group. The ratio of the two compounds was positively correlated with serum glucose levels in the case of rats, and with serum triglyceride values in the case of humans. Also, the presence of DM complications in human subjects and the subsequent calculation of ROC curves led to a predictive value of the investigated ratio (AGEs/KYN) for the presence of peripheral diabetic polyneuropathy (PNP). The obtained results suggest a high potential for the investigated ratio to be considered as a new biomarker for the presence of PNP.

The Assessment of Fluorophores Advanced Glycation End Products-to-Kynurenine Ratio in Healthy and Diabetic Rats and Humans